Cognitive Behavioral Therapy Augmentation for Treatment-Resistant Conditions

Rationale for CBT Augmentation

The American College of Cardiology is not relevant here, however, the optimal next step is to augment the current sertraline 200mg with cognitive behavioral therapy (CBT) consisting of exposure and response prevention (ERP), 10-20 sessions, while maintaining the current medication regimen, for patients with treatment-resistant conditions 1, 2
CBT augmentation has lower discontinuation rates due to adverse effects compared to pharmacological augmentation, sustained long-term benefits beyond the treatment period, and similar efficacy to pharmacological augmentation for residual symptoms, making it a preferred approach for patients with partial response to medication 2
CBT addresses all three conditions (MDD, OCD, and GAD) simultaneously, providing a comprehensive treatment approach 1, 3

The first-line approach is to add CBT with ERP protocol: 10-20 sessions, which can be delivered in-person, remotely via internet, or in group format, while continuing sertraline 200mg, already at maximum recommended dose for OCD 1
The patient should be monitored for response over 8-12 weeks while CBT is ongoing, to assess treatment efficacy and make adjustments as needed 1
If CBT is unavailable or the patient declines, the second-line approach is to add bupropion 150mg/day as pharmacological augmentation, which shows decreased depression severity with lower adverse effect discontinuation compared to buspirone 2

The patient has achieved "good response" for MDD and OCD, and augmentation strategies obtain faster response than switching compounds, making augmentation the preferred approach over switching 1
Sertraline is already at maximum dose (200mg), making dose escalation not an option, and switching to another SSRI offers no mechanistic advantage and similar side effect profiles with risk of losing current gains 1, 3
Tricyclic antidepressants are not recommended for anxiety disorders due to high anticholinergic burden, and combination of two SSRIs increases serotonin syndrome risk without evidence of benefit 3

All antidepressants carry black box warnings for increased suicidal thinking, requiring close monitoring especially during treatment transitions, and if adding pharmacological augmentation, monitor for serotonin syndrome particularly in first 24-48 hours 3
Assess response at 8-12 weeks before declaring treatment failure, to ensure adequate trial of treatment and make adjustments as needed 1